Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 16/20 | 0.43 |
| ▸ | PPARA | Q07869 | 14/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440670 | 0.82 | PPARG (0.46) | KDM4EPPARGPPARACYP3A4CYP2C9 | |
| SCHEMBL8669167 | 0.75 | KDM4E (0.46) | KDM4EFFAR1PPARGPPARACYP3A4 | |
| SCHEMBL9008047 | 0.73 | GSK3A (0.46) | KDM4EFFAR1PPARGPPARAHRH3 | |
| SCHEMBL6037064 | 0.73 | POLB (0.58) | POLB | |
| SCHEMBL8445501 | 0.73 | PPARG (0.48) | PPARGPPARACYP3A4CYP2C9KCNH2 | |
| SCHEMBL4034559 | 0.72 | KDM4E (0.73) | KDM4EFFAR1PPARGPPARAHRH3 | |
| SCHEMBL8444677 | 0.71 | PPARG (0.47) | KDM4EPPARGPPARACYP3A4CYP2C9 | |
| SCHEMBL8440666 | 0.71 | PPARG (0.47) | KDM4EPPARGPPARAPPARD | |
| SCHEMBL4031089 | 0.70 | KDM4E (0.65) | KDM4EFFAR1PPARGPPARAHRH3 | |
| SCHEMBL8662204 | 0.69 | POLB (0.39) | PPARGPPARACYP3A4CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5814647-A | ANTICARCINOGENIC AGENTS, ANTIDIABETIC AGENTS AND MENSTRUAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-09-29 | — | — | US | claimed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | claimed |
| US-5708012-A | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus | SANKYO COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | claimed |
| US-5874454-A | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus | WARNER-LAMBERT COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
| US-5814647-A | ANTICARCINOGENIC AGENTS, ANTIDIABETIC AGENTS AND MENSTRUAL DISORDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-09-29 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5708012-A | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus | SANKYO COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |